Autoantibodies against cancer antigens.
With the identification of tumor antigens, the host immune response to various types of cancers can now be studied with a high degree of specificity in large cohorts of patients, in the hope of correlating immunity with clinical events and defining immunotherapeutic strategies. Several antigens, such as NY-ESO-1, p53, or SOX2, have attracted attention because of their frequent spontaneous immunogenicity in cancer patients, notably in their ability to induce humoral responses. We describe in this chapter a simple implementation of a serological monitoring platform for autoantibody measurement in cancer patients, from production of recombinant antigens to ELISA testing and interpretation.
Gnjatic
Sacha
S
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Old
Lloyd J
LJ
Chen
Yao-Tseng
YT
D000951:Antigens, Neoplasm / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D001800:Blood Specimen Collection; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008967:Molecular Biology / Q000379:methods*
D000951:Antigens, Neoplasm; D001323:Autoantibodies